• 1
    Antoniou A, Pharoah PDP, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 72: 1117-1130.
  • 2
    Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007; 57: 75-89.
  • 3
    Ernestos B, Nikolaos P, Koulis G, et al. Increased chromosomal radiosensitivity in women carrying BRCA1/BRCA2 mutations assessed with the G2 assay. Int J Radiat Oncol Biol Phys. 2010; 76: 1199-1205.
  • 4
    Jansen-van der Weide MC, Greuter MJW, Jansen L, Oosterwijk JC, Pijnappel RM, de Bock GH. Exposure to low-dose radiation and the risk of breast cancer among women with a familial or genetic predisposition: a meta-analysis. Eur Radiol. 2010; 20: 2547-2556.
  • 5
    Berrington de Gonzalez A, Berg CD, Visvanathan K, Robson M. Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. J Natl Cancer Inst. 2009; 101: 205-209.
  • 6
    Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: an update for the US Preventive Services Task Force. Ann Intern Med. 2009; 151: 727-737.
  • 7
    Humphrey LL, Helfand M, Chan BKS, Woolf SH. Breast cancer screening: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2002; 137: 347-360.
  • 8
    Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med. 2008; 148: 671-679.
  • 9
    United States Preventive Services Task Force. Screening for breast cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009; 151: 716-726.
  • 10
    Arias E, Rostron BL, Tejada-Vera B. United States Life Tables, 2005. National Vital Statistics Reports. Hyattsville, MD: National Center for Health Statistics; 2010.
  • 11
    Horner M, Ries L, Krapcho M. SEER Cancer Statistics Review, 1975-2006 [based on November 2008 SEER data submission, posted to the SEER website 2009]. Bethesda, MD: National Cancer Institute; 2009.
  • 12
    Lee JM, Kopans DB, McMahon PM, et al. Effectiveness of MRI for breast cancer screening in BRCA1 gene mutation carriers: a Markov Monte Carlo decision analysis. Radiology. 2008; 246: 763-771.
  • 13
    Lee JM, Halpern EF, Rafferty EA, Gazelle GS, Evaluating the correlation between mammography and MRI for screening women with increased breast cancer risk. Acad Radiol. 2009; 16: 1323-1328.
  • 14
    Lee JM, McMahon PM, Kong CY, et al. Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers. Radiology. 2010; 254: 793-800.
  • 15
    Lakhani SR, van de Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002; 20: 23102318.
  • 16
    Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familiar risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005; 265: 1769-1778.
  • 17
    Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004; 351: 427-437.
  • 18
    Sardanelli F, Podo F, D'Agnolo G, et al. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. Radiology. 2007; 242: 698-715.
  • 19
    Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005; 23: 8469-8476.
  • 20
    Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004; 292: 1317-1325.
  • 21
    Hendrick RE, Pisano ED, Averbukh A, et al. Parameters and breast dose in digital mammography and screen-film mammography in the American College of Radiology Imaging Network Digital Mammographic Imaging Screening Trial. AJR Am J Roentegenol. 2010; 194: 362-369.
  • 22
    Pisano ED, Gatsonis C, Hendrick E, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med. 2005; 353: 1773-1783.
  • 23
    Pisano ED, Hendrick RE, Yaffe MJ, et al. Diagnostic accuracy of digital versus film mammography: exploratory analysis of selected population subgroups in DMIST. Radiology. 2008; 246: 376-383.
  • 24
    Preston DL, Mattsson A, Holmberg E, Shore R, Hildreth NG, Boice JDJ. Radiation effects on breast cancer risk: a pooled analysis of 8 cohorts. Radiat Res. 2002; 158: 220-235.
  • 25
    Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010; 102: 605-613.
  • 26
    Rebbeck TR, Kauff ND, Domcheck SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009; 101: 80-87.
  • 27
    Plevritis SK, Kurian AW, Sigal BM, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA. 2006; 295: 2374-2384.
  • 28
    Grann VR, Patel PR, Jacobson JS, et al. Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. Breast Cancer Res Treat. 2011; 125: 837-847.
  • 29
    Breast Cancer Screening Consortium. Frequency of node-positivity and metastatic cancer by primary tumor size and method of detection. De-identified data obtained directly from BCSC, 9/18/06.
  • 30
    Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 1687-1717.